´ëÇÑ°£ÇÐȸ (¿Â¶óÀÎ) °£¼¼Æ÷¾Ï (HCC; Early Detection and Advanced Management) : 2020-12-11±³À°ÀÏÀÚ : 2020-12-11
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) °£¼¼Æ÷¾Ï (HCC; Early Detection and Advanced Management) ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : °æ±â-ÀÎõÁöȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-707-0091
À̸ÞÀÏ :
kasl@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 0¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 2 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12¿ù 11ÀÏ ¿Â¶óÀÎ °³ÃÖ 18:00~18:40 Optimal HCC Surveillance and Current status of Korean National Liver Cancer screening program À¯Á¤ÁÖ(¼øõÇâ´ëÇб³ºÎõº´¿ø)
±³À°½Ã°£ 12¿ù 11ÀÏ ¿Â¶óÀÎ °³ÃÖ 18:40~19:20 Tyrosine kinase inhibitors or Immune checkpoint inhibitors; Which is the best treatment after sorafenib failure ±èº¸Çö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 12¿ù 11ÀÏ ¿Â¶óÀÎ °³ÃÖ 19:20~20:00 The therapeutic effect of stem cell secretome in non-alcoholic steatohepatitis and liver fibrosis model ½Å½Â°¢(°¡Ãµ´ëÇб³ ±æº´¿ø)